

UC Davis

UC Davis Previously Published Works

Title

Dominant-negative ATF5 rapidly depletes survivin in tumor cells

Permalink

<https://escholarship.org/uc/item/5w93r2qs>

Journal

Cell Death & Disease, 10(10)

ISSN

2041-4889

Authors

Sun, Xiaotian
Angelastro, James M
Merino, David
et al.

Publication Date

2019

DOI

10.1038/s41419-019-1872-y

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

ARTICLE

Open Access

Dominant-negative ATF5 rapidly depletes survivin in tumor cells

Xiaotian Sun¹, James M. Angelastro², David Merino^{1,3}, Qing Zhou¹, Markus D. Siegelin¹ and Lloyd A. Greene¹

Abstract

Survivin (*BIRC5*, product of the *BIRC5* gene) is highly expressed in many tumor types and has been widely identified as a potential target for cancer therapy. However, effective anti-survivin drugs remain to be developed. Here we report that both vector-delivered and cell-penetrating dominant-negative (dn) forms of the transcription factor ATF5 that promote selective death of cancer cells in vitro and in vivo cause survivin depletion in tumor cell lines of varying origins. dn-ATF5 decreases levels of both survivin mRNA and protein. The depletion of survivin protein appears to be driven at least in part by enhanced proteasomal turnover and depletion of the deubiquitinase USP9X. Survivin loss is rapid and precedes the onset of cell death triggered by dn-ATF5. Although survivin downregulation is sufficient to drive tumor cell death, survivin over-expression does not rescue cancer cells from dn-ATF5-promoted apoptosis. This indicates that dn-ATF5 kills malignant cells by multiple mechanisms that include, but are not limited to, survivin depletion. Cell-penetrating forms of dn-ATF5 are currently being developed for potential therapeutic use and the present findings suggest that they may pose an advantage over treatments that target only survivin.

Introduction

The transcription factor ATF5 is over-expressed in a variety of cancer types and such over-expression correlates with poor prognosis and treatment resistance^{1–18}. ATF5 is a member of the activating transcription factor family and possesses a basic leucine zipper domain that is required for association with selected partners as well as DNA binding and transcriptional activity^{2–4,19–22}. To interfere with ATF5 function, we developed a dominant-negative (dn) form of this protein that retains the native leucine zipper, but is N-terminally truncated and modified in the basic domain to abolish DNA binding and to potentially extend the leucine zipper²³. When expressed in tumor cells in vitro or in vivo, dn-ATF5 promotes their apoptotic death and causes tumor regression^{2–4,9,10,13,24}. To generate a dn-ATF5 with therapeutic potential, we

designed a form fused to a cell-penetrating “penetratin”²⁵ domain that can be produced either as a recombinant protein²⁶ or by synthesis²⁷. The presence of the cell-penetrating domain permits the penetratin-dn-ATF5 fusion peptide (CP-dn-ATF5) to rapidly pass through tissue barriers and to enter cells²⁶. Both recombinant and synthetic forms of CP-dn-ATF5 effectively promote apoptosis of a wide variety of tumor cells in vitro and in vivo^{26,27}. In contrast, neither plasmid nor penetratin delivered dn-ATF5 appears to affect survival of non-transformed cells and there have been no evident side-effects in mice treated with either the recombinant or synthetic forms of CP-dn-ATF5 at doses that suppress tumor growth^{2,24,26,27}.

The mechanisms by which dn-ATF5 promotes tumor cell death are only partially understood. dn-ATF5 decreases levels of anti-apoptotic proteins BCL2 and MCL1 in tumor cells by what appears to be both decreased transcription and elevated protein destabilization^{5,27,28}. A preliminary survey of additional proteins that regulate cell survival and death indicated that dn-ATF5 may also affect expression of the inhibitor-of-apoptosis

Correspondence: Lloyd A. Greene (lag3@cumc.columbia.edu)

¹Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA

²Department of Molecular Biosciences, University of California, Davis School of Veterinary Medicine, Davis, CA 95616, USA

Full list of author information is available at the end of the article.

Edited by G. Dewson

© The Author(s) 2019



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

protein (IAP) family member survivin (BIRC5, product of the *BIRC5* gene). Like ATF5, survivin is highly expressed in multiple tumor types with little expression in most non-transformed cells²⁹. High survivin expression in tumors is correlated with metastasis, resistance to treatment and poor prognosis^{30,31}. In addition to its action as an inhibitor of apoptosis, biological roles for survivin that also appear to contribute to its actions in tumors include regulation of cell cycle and promotion of mitochondrial function³¹. Agents that directly or indirectly down-regulate survivin levels interfere with the proliferation of cancer cells and promote their apoptotic death and thus, given survivin's absence from most non-transformed cells, it has been widely considered as an attractive potential target for cancer treatment^{30–36}. Consequently, there has been substantial effort to identify/generate agents that suppress survivin expression in neoplasias^{31,33–36}. To date, no such drug has reached clinical use beyond trials, neither as a mono- or combination therapy. Thus there is a continued need to identify agents that affect survivin expression and that have the potential to be used as safe cancer therapeutics.

Materials and methods

Cells culture and transfection

GBM12 cells were kindly supplied by Dr. Jann Sarkaria (Mayo Clinic). All other cell lines were obtained from the ATCC and authenticated by the supplier. All lines were grown in DMEM supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 U/ml streptomycin. siUSP9X (#6308 S, Cell Signaling Technology, Danvers MA), siSurvivin (#6351, Cell Signaling Technology; #4390824, Silencer Select S1458, Ambion), siRNA CTR (#6568, Cell Signaling Technology; SilencerTM Select Negative Control, #4390843, Ambion) were transfected into cells using OligofectamineTM Transfection Reagent (Invitrogen, Waltham MA) following the supplier's protocols. All plasmids were transfected by using LipofectamineTM 3000 (Invitrogen) following the supplier's protocols.

Plasmids

FLAG-tagged human survivin cDNA cloned into a pCMV6-entry vector was obtained from Origene, Rockville MD (#RC205935). The plasmid used for FLAG-survivin over-expression was pLVX-EF1 α -IRES-mCherry (#631987, Takara Bio USA, Mountainview CA), a bicistronic lentiviral vector allowing the expression of the transgene and mCherry under the control of the EF1 α promoter. FLAG-survivin was generated and cloned in the pLVX vector using primers AAGAATTC (EcoRI) ATGGGTGCCCGACGTTG and AATCTAGA(XbaI) TTA CTTATCGTCGTCATC. GFP-BCL2³⁷ was a gift from Clark Distelhorst (Addgene plasmid # 17999; <http://n2t.net/addgene:17999>; RRID:Addgene_17999).

Indicated experiments employed wild-type and mutant pCMV-1A-3xFLAG-dn-ATF5. To generate these constructs, DNA optimized for human codon usage with a 5'-BamHI site and a 3'-XhoI site were synthesized as gBlock fragments (Integrated DNA Technologies Inc, Skokie IL) encoding the wild-type dn-ATF5 sequence, MASMTGGQQMGRDPDLEQRAEELARENEELLEKEAEELEQENAELEGECQGLEARNREL RERAESVEREIQYVKDLLIEVYKARSQRTRSA, or encoding a mutant form of dn-ATF5, MASMTGGQQMGRDPDGEQRAEEGARENEEGEKEAEEGEQENAE GEGECQGG EARNREG RERAESVEREIQYVKDGGIEVYKARSQRTRSA in which the indicated (bolded) leucines were replaced with glycines to inactivate leucine zipper activity. The fragments were subcloned into the BamHI and XhoI site of pCMV-3Tag-1A (Agilent Technologies Inc, Santa Clara CA) plasmid for in frame N-terminal 3XFlag-tagged expression of dn-ATF5 or mutant dn-ATF5. Where indicated, experiments additionally employed pLe-FLAG-GFP-dn-ATF5 as previously described²³.

Lentivirus preparation

Lentivirus were prepared in HEK293 cells by co-transfecting pLVX expression plasmids along with second generation lentiviral packaging plasmids using the calcium phosphate transfection method as previously described³⁸. Lentiviral particles were collected, then concentrated using Lenti-X concentrator (#631231, Takara), resuspended in PBS, and stored at -80°C .

For lentiviral infection, 0.1 up to 5×10^7 viral particles were added per cm^2 of culture area, directly in the culture medium. The transduced cells were analyzed by qPCR, Western blot or flow cytometry after 3–5 days.

Flow cytometry

Cells were dissociated with trypsin, and washed with cold PBS twice, then resuspended in 1 X binding buffer at a concentration of 1×10^6 cells/ml. About 100 μl of the solution (1×10^5 cells) were incubated with 5 μl of FITC Annexin V and 5 μl PI (#556547, BD, Franklin Lakes NJ) for 15 min at room temperature in the dark. The cell suspension was mixed with 400 μl of 1X binding buffer and analyzed by flow cytometry.

qPCR

Cells were lysed and total RNA was purified using TRI reagent (Molecular Research Center, Cincinnati OH) following the manufacturer's protocol. 1 μg of mRNA was used for the synthesis of cDNA using the first-strand cDNA synthesis kit (Origene). qPCR was performed using FastStart SYBR Green Master Mix (Roche, Indianapolis IN) by using the following primer pairs: h-Survivin, CCACTGAGAACGAGCCAGACTT and GTATTACAGGCGTAAGCCACCG; h-18S RNA, AGTCCCTGCCCT

TTGTACACA and GATCCGAGGGCCTCACTAAAC. The relative mRNAs levels for genes of interest were normalized to 18 S RNA.

Western immunoblotting

Cells were homogenized in cell lysis buffer (#9803, Cell Signaling Technology, Danvers MA) with protease inhibitor mixture (#11836170001, Roche). Protein samples were prepared in X2 loading buffer (#161-0737, BioRad, Portland ME) with β ME following the manufacturer's instruction. Protein was loaded and separated by electrophoresis and then transferred onto PVDF membranes (Bio-Rad). Blots were probed with the following primary antibodies: rabbit anti-survivin (#2808, Cell Signaling Technology), anti-FLAG (#8146, Cell Signaling Technology), mouse anti-ACTIN (#3700, Cell Signaling Technology), rabbit anti-USP9X (#5751, Cell Signaling Technology). All band intensities were determined using ImageJ and normalized to ACTIN signal.

Immunofluorescence

Cells were fixed for 10 min in 4% PFA, washed 3 times with PBS, and blocked with Superblock (#37515 Thermo Fisher Scientific, Waltham MA) with 0.3% Triton-X for 30 min at room temperature. The following primary antibodies were used for immunofluorescence: rabbit anti-FLAG (#14793, Cell Signaling Technology), rabbit anti-GFP (# PA5-22688, Invitrogen), rabbit anti-survivin (#2808, Cell Signaling Technology). Hoechst 33328 was used to stain nuclei. Images were acquired using a Zeiss epifluorescence microscope equipped with a digital camera and Axiovision software.

Results

Expression of dn-ATF5 depletes nuclear survivin expression in tumor cells prior to promotion of apoptotic cell death

We previously reported that expression of dn-ATF5-encoding plasmids promotes apoptotic death of a wide range of tumor cell types, but not of non-transformed cells^{2,3,24}. As an initial approach to assessing the potential effect of dn-ATF5 on survivin expression, we transfected PC3 prostate tumor cells with a previously described construct expressing GFP-FLAG-dn-ATF5²³ and determined total survivin levels by western immunoblotting after 3 days (Fig. 1a). This revealed an approximate 40% loss of survivin protein expression (not accounting for a transfection efficiency of 50–70%).

Similar results were achieved by transfecting T98G glioblastoma cells with 3xFLAG-dn-ATF5 (Supplementary Fig. 1). We also carried out a parallel transfection with a mutated form of this construct in which the critical leucine residues in the leucine zipper were replaced with glycine residues. We previously found that such


replacements in a dn form of ATF5 compromises its capacity to promote cell death²⁷. In contrast to the non-mutated construct, the mutant construct failed to down-regulate survivin (Supplementary Fig. 1). Taken together, these findings indicate that dn-ATF5 reduces survivin expression in tumor cells and that this requires a functional leucine zipper domain.

To further assess effects of dn-ATF5 on survivin expression and localization at the cellular level, we transfected T98G and LN229 glioblastoma cells with a GFP-FLAG-dn-ATF5 construct or with a control plasmid expressing only GFP. One day after transfection, transfected (GFP+) cells were immunostained for survivin expression and blindly scored for proportions with either no, cytoplasmic/nuclear (cells with evident survivin expression in both nuclei and cytoplasm) or nuclear-only localized survivin (Fig. 1b). In both lines, about 60% of control cells showed nuclear-only localization, about 25% cytoplasmic/nuclear staining and about 15% no detectable survivin staining (Fig. 1c). In contrast, there was an approximate 3-fold increase in proportion of cells without detectable survivin expression (to almost 50% of the population) (Fig. 1c) after transfection with GFP-FLAG-dn-ATF5. This appeared to come mainly at the expense of nuclear survivin for which there was a corresponding loss in proportion of cells with immunostaining in this compartment (Fig. 1c). These effects were sustained in that they were also evident 3–5 days after transfection (Fig. 1d).

As noted above, dn-ATF5 expression triggers extensive apoptotic death of tumor cells. This raised the question as to whether survivin depletion might either precede or be a result of the death process. We therefore monitored the proportions of cells with apoptotic nuclei at 1–5 days after transfection. In agreement with prior findings², this revealed no increase in apoptosis compared to controls at 24 h after transfection (Fig. 1e), a time when survivin expression was already diminished. This contrasted with later times when both loss of survivin and increased apoptotic death were apparent (Fig. 1f). Thus, survivin appears to be lost prior to the appearance of apoptotic nuclei and to be sustained during the death process.

Cell penetrant synthetic CP-dn-ATF5 depletes survivin protein in multiple tumor cell lines

We previously described a synthetic version CP-dn-ATF5 that contains a penetratin domain that permits rapid cellular uptake of the peptide and that promotes apoptotic death of a wide variety of tumor types *in vitro* and *in vivo*^{26,27}. We therefore next tested whether this potential therapeutic prototype form of dn-ATF5 would also affect tumor cell survivin protein levels. CP-dn-ATF5 has the advantage that it rapidly reaches all cells in cultures and that the effects on survivin can therefore be readily quantified. We initially treated T98G, U87 and



LN229 cells with 50, 100, and 200 μ M CP-dn-ATF5 for 24 h and assessed relative survivin levels. These concentrations of CP-dn-ATF5 have little effect on cell survival or numbers at 24 h, and trigger apoptotic death in a dose-responsive manner beginning at 2 days and strongly manifest at 3 days of treatment²⁷. The data reveal a consistent loss of survivin protein within 24 h with some degree of variability from experiment to experiment (Fig. 2a, b).

We next applied single doses of 50, 100, and 200 μ M CP-dn-ATF5 to 12 different human tumor cell lines of various origins (prostate [PC3, DU145], colon [HCT116], glioblastoma [U251, U87, T98G, LN229, and GBM12], breast [MDA-MB-231, BT474, MDA-MB-468 and MCF7] for 1–3 days and then measured the relative levels of survivin protein. Dose-dependent reductions in survivin protein were seen in all lines at 24 h and persisted for the 3 days of treatment with a range of responses, reaching




Fig. 2 Treatment with CP-dn-ATF5 causes a dose- and time-dependent depletion of survivin protein in multiple cancer cell lines prior to loss of cell viability. a, b CP-dn-ATF5 depletes survivin in T98G, U87 and LN229 glioblastoma cell lines at 24 h after treatment. **a** Representative western blots. **b** Data are from three independent experiments. **c** CP-dn-ATF5 depletes survivin in T98G, U87 and LN229 glioblastoma cell lines at 48 and 72 h after treatment. Normalized survivin to ACTIN ratios are shown for each lane. **d** Treatment with CP-dn-ATF5 causes a rapid depletion of survivin protein in T98G cultures. Normalized survivin to ACTIN ratios are shown for each lane. **e** Cell death caused by CP-dn-ATF5 (100 μM) in T98G cultures occurs after survivin depletion. Relative numbers of cells per culture were determined at the indicated times. Three replicate cultures were evaluated at each time point

survivin depletion of over 90% in some cases (Fig. 2c and Supplementary Fig. 2).

We also examined the onset time of survivin protein loss with CP-dn-ATF5 at 100 μM in T98G cultures. There was no significant effect at 4 h, but reduction of survivin levels was evident at 8 h and beyond (Fig. 2d). To determine

whether this depletion of survivin might be the result of cell death, we also assessed cell viability over time and confirmed no loss of cells at 24 h with death evident only at 48 and 72 h (Fig. 2e). Taken together, our data indicate that CP-dn-ATF5 depletes survivin levels in multiple tumor lines and appears to do so well before the appearance of cell death.

CP-dn-ATF5 depletes survivin mRNA in multiple tumor cell lines

To determine whether CP-dn-ATF5 affects levels of survivin mRNA as well as protein, we carried out qPCR on the 12 cell lines listed above after a single dose exposure to 50, 100, or 200 μM peptide for 48 h. In each case, there was substantial depletion of survivin mRNA, with a range of responsiveness among the lines (Fig. 3a–d). Additional analyses of survivin mRNA in multiple lines showed time and dose-dependent loss of survivin mRNA at 24 and 72 h of treatment with changes apparent within 24 h (Supplementary Figs. 3 and 4). A time course study of survivin mRNA levels in T98G cells (Fig. 3e) parallel to that described above for survivin protein (Fig. 2d) revealed that survivin transcripts were already substantially decreased by 4 h of CP-dn-ATF5 exposure. This well precedes the onset of cell death in such cells and occurs before depletion of survivin protein (Fig. 2e).


CP-dn-ATF5 depletes virally-expressed exogenous survivin protein in multiple tumor cell lines


While our results indicate that CP-dn-ATF5 causes survivin mRNA depletion, the possibility remained that CP-dn-ATF5 also causes survivin protein loss by promoting its turnover. To assess this, we infected multiple

tumor lines with lentivirus expressing FLAG-tagged survivin driven by a CMV promoter. Despite expression of the protein from a heterologous promoter, exposure to 100 μM CP-dn-ATF5 for 3 d caused substantial reduction in expression of the exogenous survivin protein in all lines tested (Fig. 4a). This observation suggests that CP-dn-ATF5 causes depletion of survivin protein at least partly by mechanisms independent from its effects on survivin mRNA.

CP-dn-ATF5 destabilizes cellular survivin protein and promotes survivin loss via proteasomal degradation

We next examined whether, as appears for over-expressed survivin, CP-dn-ATF5-promoted reduction of endogenous survivin also involves a non-transcriptional mechanism. Prior reports indicate that cellular survivin levels are subject to post-transcriptional regulation by degradation^{39,40}. To assess whether CP-dn-ATF5 affects survivin stability, we pretreated T98G cells with or without this peptide for 24 h and then exposed them to the translational inhibitor cycloheximide for various times before determining relative survivin protein levels by western immunoblotting. As shown in Fig. 4b, c, this revealed that CP-dn-ATF5 significantly accelerates survivin turnover under conditions when survivin synthesis is





blocked. These findings thus indicate that survivin depletion caused by dn-ATF5 likely reflects decreased survivin protein stability.

To approach the issue of the mechanism by which dn-ATF5 affects survivin stability, we generated T98G cells stably over-expressing FLAG-survivin on a heterologous promoter. To determine whether the post-translational component of the effect of CP-dn-ATF5 on survivin is mediated by the proteasome, we exposed the survivin


over-expressing cells to 100 μ M CP-dn-ATF5 for 24 h in presence or absence of the proteasomal inhibitor epoxomicin (Fig. 5a). Under such circumstances, FLAG-survivin levels decreased with CP-dn-ATF5 alone by about 50% compared with untreated controls; with epoxomicin alone, FLAG-survivin levels rose by about three-fold and this level was not reduced by CP-dn-ATF5 co-treatment. Taken together, these data thus indicate that CP-dn-ATF5 decreases survivin stability and support the idea that enhanced proteasomal turnover contributes to survivin depletion caused by CP-dn-ATF5.

USP9X depletion contributes to the CP-dn-ATF5-mediated decrease in survivin stability

We next explored the mechanism by which CP-dn-ATF5 treatment leads to survivin protein destabilization. The deubiquitinase USP9X has been shown to deubiquitinate survivin and thus potentially to inhibit its proteasomal degradation⁴¹. Although USP9X downregulation in HeLa cells was reported without effect on survivin protein levels⁴¹, similar downregulation of USP9X in SF188 and Panc-1 cells resulted in survivin protein depletion^{42,43}. Our past work has shown that CP-dn-ATF5 dramatically reduces USP9X levels in multiple tumor cell lines including T98G cells²⁷. We therefore asked whether such an effect of CP-dn-ATF5 on USP9X in T98G cells could contribute to the depletion of survivin seen with this agent. Accordingly, we used a previously described USP9X-directed siRNA²⁷ to knockdown USP9X and compared survivin levels with those in cells receiving a control siRNA. This revealed a significant loss of survivin protein (Fig. 5b), but not survivin mRNA (Fig. 5c), thus indicating that the reduction of USP9X caused by CP-dn-ATF5 treatment likely contributes to survivin protein depletion.

Is survivin depletion by CP-dn-ATF5 sufficient to account for the anti-tumor actions of this agent?


Numerous studies have documented that reduction of survivin levels is sufficient to promote death of various tumor cell types^{30–32,34}. We confirmed this with an siRNA targeting survivin in T98G, HCT116, MCF7, and MDA-MB-468 cells that induced apoptotic death in each case (Supplementary Fig. 5). However, while direct targeting of survivin expression has been raised as a potential treatment for a variety of cancers, to this point, no successful anti-survivin monotherapy has emerged. In this context, we thus asked whether the capacity of CP-dn-ATF5 to deplete survivin is necessary for its ability to promote tumor cell death or whether this agent also has additional death-promoting activities. To address this, we first over-expressed FLAG-survivin in T98G tumor cells and then assessed the capacity of CP-dn-ATF5 to promote their death. As shown in Fig. 6a, although CP-dn-ATF5



reduced the expression of the FLAG-survivin as anticipated, even under these conditions exogenous survivin was expressed at far higher levels than the corresponding endogenous protein. Despite such high survivin over-expression, it failed to significantly protect T98G cells from death caused by 3 days of CP-dn-ATF5 treatment as indicated by morphology (Fig. 6b), percentage of apoptotic cells as determined by flow analysis (6C), or cell numbers (6D). We also observed similar results by flow analysis of U87 cells and by cell counts of LN229, GBM12, MDA-MB-231, U251, and DU145 cultures transfected to over-express survivin (Supplementary Figs. 6, 7). Finally, to control for the possibility that CP-dn-ATF5 kills survivin over-expressing tumor cells by a mechanism apart from its dn-ATF5 activity, we also asked whether survivin over-expression would rescue cells transfected with the pLe-GFP-FLAG-dn-ATF5 plasmid. As shown in Fig. 6e, over-expressed survivin also failed to protect from plasmid-delivered dn-ATF5. These findings thus support the conclusion that while CP-dn-ATF5 rapidly depletes cells of survivin, it has additional actions that can promote

cell death that cannot be rescued by survivin over-expression.

The inability of survivin over-expression to rescue tumor cells from the lethal effects of dn-ATF5 exposure raised the question of whether CP-dn-ATF5 might kill tumor cells by a non-apoptotic mechanism. Our past work showed that tumor cell death promoted by transfected dn-ATF5 plasmid is apoptotic in nature and is blocked by inhibition of caspase activity². We confirmed this for CP-dn-ATF5 in the present study in which the caspase inhibitor zVAD rescued cell numbers and the occurrence of apoptotic nuclei from the effects of 3 days of peptide exposure (Supplementary Fig. 8). Past work has shown that dn-ATF5 expression leads to downregulation of pro-survival BCL2^{9,27,28}. We therefore additionally assessed whether BCL2 over-expression would protect T98G cells from 3 days of CP-dn-ATF5 treatment. While Bcl2 over-expression reduced the presence of apoptotic nuclei, such protection from CP-dn-ATF5 was only partial (Supplementary Fig. 9). Taken together, these findings support the idea that dn-ATF5 promotes caspase-



dependent apoptotic death of cancer cells and that it does so by multiple pro-apoptotic actions including down-regulation of survivin and BCL2. Moreover, owing to the multiplicity of these actions, replacement of a single pro-survival protein such as survivin is insufficient to maintain viability.

Discussion

The present findings establish that dn-ATF5 consistently depletes survivin expression in a wide variety of human tumor cell lines. This appears to occur by both decreases in levels of survivin mRNA and enhanced survivin turnover. These decreases occur rapidly and are durable. Given survivin's roles in cancer cell proliferation, survival, metastasis, and therapeutic resistance^{30–32,34,35}, dn-ATF5-induced survivin depletion is highly likely to contribute to dn-ATF5's anti-tumor actions.

We observed that both plasmid-encoded and a penetratin-linked synthetic forms of dn-ATF5-promoted survivin depletion. The plasmid-encoded form has N-terminal GFP and FLAG tags followed by a linker region and retains the 25 amino acids C-terminal to the leucine zipper domain of ATF5. These sequences are not present in CP-dn-ATF5²⁷, thus indicating that they are neither required for, nor interfere with, the capacity of dn-ATF5 to deplete survivin. Likewise, addition of the N-terminal penetratin domain in the synthetic form does not appear to interfere with its capacity to regulate survivin expression.

It was also conceivable that plasma-encoded and penetratin-linked dn-ATF5 might be present in different subcellular compartments that would result in distinct effects on survivin levels. This did not appear to be the case, indicating that both forms have similar activities. We also evaluated a form of 3xFLAG-dn-ATF5 mutated in the leucine zipper domain. This mutant form failed to deplete survivin, demonstrating that leucine zipper function is indispensable for dn-ATF5's capacity to affect survivin expression.

One potential issue about the effects of dn-ATF5 on survivin expression was whether this was a response to, rather than contributor to, apoptotic death. Our findings with both transfected and penetratin-linked dn-ATF5 showed depletion of survivin mRNA and protein well before onset of cell death, thus supporting a role for survivin depletion as a primary contributor rather than responder to cell death triggered by dn-ATF5.

Our findings indicate that dn-ATF5 selectively depletes nuclear-localized survivin. It has been reported that survivin turns over more efficiently in nuclei^{44–46}. In this light, given that dn-ATF5 rapidly diminishes survivin mRNA levels, loss of nuclear survivin may reflect decreased survivin synthesis that cannot keep up with the level of degradation in this compartment. Additionally, or

alternatively, dn-ATF5 may affect survivin movement between the cytoplasmic and nuclear compartments, so that nuclear import is reduced or export is increased. In either case, loss of nuclear localization would suggest that at least one consequence of survivin depletion by dn-ATF5 is defective cell cycle progression.

The mechanisms that underlie the depletion of survivin by dn-ATF5 appear to be complex with both reduction of mRNA levels and post-translational degradation playing roles (Fig. 7). It is presently unknown whether survivin is a direct or indirect transcriptional target of ATF5 or whether dn-ATF5 might act by binding and sequestering another partner that influences survivin mRNA or protein expression. Our findings that dn-ATF5 reduces expression of survivin protein encoded by plasmids with heterologous promoters and that it accelerates turnover of endogenous survivin establish a role for a post-translational mechanism in survivin depletion. Prior work shows that survivin is subject to proteasomal degradation^{39,40}. Consistent with this, we found that the proteasomal inhibitor epoxomicin elevated expression of transfected FLAG-survivin. We also observed that epoxomicin blocked the depletion of FLAG-survivin by CP-dn-ATF5, a finding that supports the idea that one mechanism by which dn-ATF5 reduces survivin is by promoting its proteasomal destruction. Survivin appears to be protected from proteasomal degradation by interaction with partners such as HSP90⁴⁷ and by deubiquitination by enzymes including USP9X^{42,43}. We previously reported that CP-dn-ATF5 substantially reduces expression of USP9X in a variety of tumor cell lines²⁷. This raised the possibility that enhanced survivin turnover by dn-ATF5 is mediated at least in part by USP9X depletion (Fig. 7) and in support of this, we found that USP9X knockdown in T98G cells results in a significant reduction of survivin protein levels.

Among the issues explored here was whether survivin depletion fully accounts for the apoptotic activity of dn-ATF5. The degree of survivin depletion in many cell lines achieved with dn-ATF5 (in some cases, >90%) was on the order reached by survivin si- or sh-RNA treatments that




Fig. 7 Proposed role of survivin regulation in the mechanism by which dn-ATF5 kills tumor cells

elicit apoptotic tumor cell death. Thus, it appears that the depletion of survivin caused by dn-ATF5 is likely to be sufficient to cause death. On the other hand, our experiments indicated that death of tumor cells promoted by CP-dn-ATF5 was not rescued by survivin over-expression. This suggests that dn-ATF5 triggers pro-apoptotic events in addition to survivin depletion that are sufficient to kill cancer cells. Thus far, additional identified actions of dn-ATF5 that could contribute to its apoptotic actions include depletion of MCL1 and BCL2^{5,10,27,28} (Fig. 7) and it is highly likely that more remain to be identified. The potential capacity of dn-ATF5 therapeutics to deplete survivin as well as other survival-promoting proteins may represent an advantage over drugs such as siRNAs that target only survivin.

In addition to promoting cancer cell death as monotherapies, agents that reduce survivin expression or activity are reported to sensitize tumor cells to chemotherapeutics or radiation^{30–35}. Because dn-ATF5 depletes survivin in tumor cells, this suggests that it may also serve in combination therapies to overcome therapeutic resistance. This possibility is supported by reports that dn-ATF5 sensitizes pancreatic cancer cells to paclitaxel⁹ and that ATF5 promotes radioresistance of lung cancer cells¹¹.

Acknowledgements

This work was supported in part by grants from the NIH-NINDS (1R01NS083795 (J.M.A. and L.A.G.), K08 award K08NS083732 (M.D.S.)), Sapience Therapeutics (L.A.G.) and the Thompson Family Foundation Initiative at Columbia University (L.A.G.). We also thank Sapience Therapeutics for the generous gift of ST-36 (CP-dn-ATF5). We thank Mrs. Chang Shu for superb technical assistance.

Author contributions

X.S. contributed to design and execution of all experiments, played an important role in interpreting the results, and participated in drafting and revising the manuscript. J.M.A. generated key reagents, contributed to experimental design and interpretation of results and to revising the manuscript. D.M. contributed to data acquisition and to revising of the manuscript. Q.Z. contributed to data acquisition and interpretation, M.D.S. provided key preliminary data, and contributed to conception of the project and experimental design and to revision of the manuscript. L.A.G. contributed to conception of the project, to experimental design and interpretation and to drafting and preparation of the manuscript. In Figs. 1–6 and supplemental Figs. 1–9, X.S. generated data in all panels. X.S. and L.A.G. prepared and assembled the panels. In Fig. 1, L.A.G. contributed to generation of data (scoring of survivin localization) in panels c and d. D.M. contributed data in Fig. 1, panels b–f; Fig. 2, panels a, b, d; and to Fig. 3B. Q.Z. contributed to generation of data for supplemental Fig. 5, panels d–h.

Author details

¹Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA. ²Department of Molecular Biosciences, University of California, Davis School of Veterinary Medicine, Davis, CA 95616, USA. ³Present address: CMI Strategies, Boulogne-Billancourt, 80 rue Gallieni, cedex, France

Conflict of interest

L.A.G. and J.M.A. are listed as co-inventors on a patent entitled “Methods for promoting apoptosis and treating tumor cells by inhibiting the expression or function of the transcription factor ATF5” which is owned by Columbia University and on patent “Compositions and Methods for Inhibiting Tumor

Cells by Inhibiting the Transcription Factor ATF5,” which is owned by Columbia University and University of California, Davis. L.A.G. and J.M.A. were compensated scientific advisory board members of Sapience Therapeutics which has licensed dn-ATF5 technology from Columbia University. Columbia University holds equity in Sapience Therapeutics. No potential conflicts of interest were disclosed by the other authors.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information accompanies this paper at (<https://doi.org/10.1038/s41419-019-1872-y>).

Received: 22 January 2019 Revised: 22 July 2019 Accepted: 8 August 2019
Published online: 24 September 2019

References

- Dong, S. et al. Histology-based expression profiling yields novel prognostic markers in human glioblastoma. *J. Neuropathol. Exp. Neurol.* **64**, 948–955 (2005).
- Angelastro, J. M. et al. Selective destruction of glioblastoma cells by interference with the activity or expression of ATF5. *Oncogene* **25**, 907–916, <https://doi.org/10.1038/sj.onc.1209116> (2006).
- Monaco, S. E., Angelastro, J. M., Szabolcs, M. & Greene, L. A. The transcription factor ATF5 is widely expressed in carcinomas, and interference with its function selectively kills neoplastic, but not nontransformed, breast cell lines. *Int. J. Cancer* **120**, 1883–1890, <https://doi.org/10.1002/ijc.22469> (2007).
- Greene, L. A., Lee, H. Y. & Angelastro, J. M. The transcription factor ATF5: role in neurodevelopment and neural tumors. *J. Neurochem.* **108**, 11–22, <https://doi.org/10.1111/j.1471-4159.2008.05749.x> (2009).
- Sheng, Z. et al. A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications. *Nat. Med.* **16**, 671–677, <https://doi.org/10.1038/nm.2158> (2010).
- Sheng, Z., Evans, S. K. & Green, M. R. An activating transcription factor 5-mediated survival pathway as a target for cancer therapy? *Oncotarget* **1**, 457–460, <https://doi.org/10.18632/oncotarget.100914> (2010).
- Li, G., Xu, Y., Guan, D., Liu, Z. & Liu, D. X. HSP70 protein promotes survival of C6 and U87 glioma cells by inhibition of ATF5 degradation. *J. Biol. Chem.* **286**, 20251–20259, <https://doi.org/10.1074/jbc.M110.211771> (2011).
- Kong, X. et al. Overexpression of activating transcription factor 5 in human rectal cancer. *Exp. Ther. Med.* **2**, 827–831, <https://doi.org/10.3892/etm.2011.295> (2011).
- Hu, M. et al. Interference with ATF5 function enhances the sensitivity of human pancreatic cancer cells to paclitaxel-induced apoptosis. *Anticancer Res.* **32**, 4385–4394 (2012).
- Chen, A. et al. ATF5 is overexpressed in epithelial ovarian carcinomas and interference with its function increases apoptosis through the downregulation of Bcl-2 in SKOV-3 cells. *Int. J. Gynecol. Pathol.* **31**, 532–537, <https://doi.org/10.1097/PGP.0b013e31824df26b> (2012).
- Ishihara, S. et al. Activating transcription factor 5 enhances radioresistance and malignancy in cancer cells. *Oncotarget* **6**, 4602–4614, <https://doi.org/10.18632/oncotarget.2912> (2015).
- Nukuda, A. et al. Role of ATF5 in the invasive potential of diverse human cancer cell lines. *Biochem. Biophys. Res. Commun.* **474**, 509–514, <https://doi.org/10.1016/j.bbrc.2016.04.131> (2016).
- Angelastro, J. M. Targeting ATF5 in Cancer. *Trends Cancer* **3**, 471–474, <https://doi.org/10.1016/j.trecan.2017.05.004> (2017).
- Wang, M. et al. miR-141-3p functions as a tumor suppressor modulating activating transcription factor 5 in glioma. *Biochem. Biophys. Res. Commun.* **490**, 1260–1267, <https://doi.org/10.1016/j.bbrc.2017.05.179> (2017).
- Deng, P. & Haynes, C. M. Mitochondrial dysfunction in cancer: Potential roles of ATF5 and the mitochondrial UPR. *Semin. Cancer Biol.* **47**, 43–49, <https://doi.org/10.1016/j.semcancer.2017.05.002> (2017).
- Hu, M. et al. Human cytomegalovirus immediate-early protein promotes survival of glioma cells through interacting and acetylating ATF5. *Oncotarget* **8**, 32157–32170, <https://doi.org/10.18632/oncotarget.17150> (2017).

17. Ben-Shmuel, S. et al. Activating Transcription Factor-5 Knockdown Reduces Aggressiveness of Mammary Tumor Cells and Attenuates Mammary Tumor Growth. *Front. Endocrinol.* (Lausanne) **8**, 173, <https://doi.org/10.3389/fendo.2017.00173> (2017).
18. Feldheim, J. et al. Expression of activating transcription factor 5 (ATF5) is increased in astrocytomas of different WHO grades and correlates with survival of glioblastoma patients. *Oncotargets Ther.* **11**, 8673–8684, <https://doi.org/10.2147/OTT.S176549> (2018).
19. Hansen, M. B. et al. Mouse Atf5: molecular cloning of two novel mRNAs, genomic organization, and odorant sensory neuron localization. *Genomics* **80**, 344–350 (2002).
20. Al Sarraj, J., Vinson, C. & Thiel, G. Regulation of asparagine synthetase gene transcription by the basic region leucine zipper transcription factors ATF5 and CHOP. *Biol. Chem.* **386**, 873–879, <https://doi.org/10.1515/BC.2005.102> (2005).
21. Potapov, V., Kaplan, J. B. & Keating, A. E. Data-driven prediction and design of bZIP coiled-coil interactions. *PLoS Comput. Biol.* **11**, e1004046, <https://doi.org/10.1371/journal.pcbi.1004046> (2015).
22. Sears, T. K. & Angelastro, J. M. The transcription factor ATF5: role in cellular differentiation, stress responses, and cancer. *Oncotarget* **8**, 84595–84609, <https://doi.org/10.18632/oncotarget.21102> (2017).
23. Angelastro, J. M. et al. Regulated expression of ATF5 is required for the progression of neural progenitor cells to neurons. *J. Neurosci.* **23**, 4590–4600 (2003).
24. Arias, A. et al. Regulated ATF5 loss-of-function in adult mice blocks formation and causes regression/eradication of gliomas. *Oncogene* **31**, 739–751, <https://doi.org/10.1038/onc.2011.276> (2012).
25. Dupont, E., Prochiantz, A. & Joliet, A. Penetratin story: an overview. *Methods Mol. Biol.* **1324**, 29–37, https://doi.org/10.1007/978-1-4939-2806-4_2 (2015).
26. Cates, C. C. et al. Regression/eradication of gliomas in mice by a systemically-deliverable ATF5 dominant-negative peptide. *Oncotarget* **7**, 12718–12730, <https://doi.org/10.18632/oncotarget.7212> (2016).
27. Karpel-Massler, G. et al. A synthetic cell-penetrating dominant-negative ATF5 peptide exerts anticancer activity against a broad spectrum of treatment-resistant cancers. *Clin. Cancer Res.* **22**, 4698–4711, <https://doi.org/10.1158/1078-0432.CCR-15-2827> (2016).
28. Dluzen, D., Li, G., Tselosky, D., Moreau, M. & Liu, D. X. BCL-2 is a downstream target of ATF5 that mediates the prosurvival function of ATF5 in a cell type-dependent manner. *J. Biol. Chem.* **286**, 7705–7713, <https://doi.org/10.1074/jbc.M110.207639> (2011).
29. Ambrosini, G., Adida, C. & Altieri, D. C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. *Nat. Med.* **3**, 917–921 (1997).
30. Altieri, D. C. Targeting survivin in cancer. *Cancer Lett.* **332**, 225–228, <https://doi.org/10.1016/j.canlet.2012.03.005> (2013).
31. Altieri, D. C. Survivin—The inconvenient IAP. *Semin. Cell Dev. Biol.* **39**, 91–96, <https://doi.org/10.1016/j.semcdb.2014.12.007> (2015).
32. Cheung, C. H. et al. Survivin—biology and potential as a therapeutic target in oncology. *Oncotargets Ther.* **6**, 1453–1462, <https://doi.org/10.2147/OTT.S33374> (2013).
33. Athanasoula, K. et al. Survivin beyond physiology: orchestration of multistep carcinogenesis and therapeutic potentials. *Cancer Lett.* **347**, 175–182, <https://doi.org/10.1016/j.canlet.2014.02.014> (2014).
34. Peery, R. C., Liu, J. Y. & Zhang, J. T. Targeting survivin for therapeutic discovery: past, present, and future promises. *Drug Discov. Today* **22**, 1466–1477, <https://doi.org/10.1016/j.drudis.2017.05.009> (2017).
35. Li, D., Hu, C. & Li, H. Survivin as a novel target protein for reducing the proliferation of cancer cells. *Biomed. Rep.* **8**, 399–406, <https://doi.org/10.3892/br.2018.1077> (2018).
36. Martinez-Garcia, D., Manero-Ruperez, N., Quesada, R., Korrodi-Gregorio, L. & Soto-Cerrato, V. Therapeutic strategies involving survivin inhibition in cancer. *Med. Res. Rev.* <https://doi.org/10.1002/med.21547> (2018).
37. Wang, N. S., Unkila, M. T., Reineks, E. Z. & Distelhorst, C. W. Transient expression of wild-type or mitochondrially targeted Bcl-2 induces apoptosis, whereas transient expression of endoplasmic reticulum-targeted Bcl-2 is protective against Bax-induced cell death. *J. Biol. Chem.* **276**, 44117–44128, <https://doi.org/10.1074/jbc.M101958200> (2001).
38. Aime, P., Sun, X., Greene, L. A. *Gene Expression and Regulation in Mammalian Cells* Ch. 11. (IntechOpen, London, 2018).
39. Zhao, J., Tenev, T., Martins, L. M., Downward, J. & Lemoine, N. R. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. *J. Cell Sci.* **113**(Pt 23), 4363–4371 (2000).
40. Liu, Y. et al. The proapoptotic F-box protein Fbx17 regulates mitochondrial function by mediating the ubiquitylation and proteasomal degradation of survivin. *J. Biol. Chem.* **290**, 11843–11852, <https://doi.org/10.1074/jbc.M114.629931> (2015).
41. Vong, Q. P., Cao, K., Li, H. Y., Iglesias, P. A. & Zheng, Y. Chromosome alignment and segregation regulated by ubiquitination of survivin. *Science* **310**, 1499–1504, <https://doi.org/10.1126/science.1120160> (2005).
42. Karpel-Massler, G. et al. Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo. *Oncotarget* **7**, 12791–12805, <https://doi.org/10.18632/oncotarget.7302> (2016).
43. Liu, L. et al. Deubiquitinase USP9X promotes cell migration, invasion and inhibits apoptosis of human pancreatic cancer. *Oncol. Rep.* **38**, 3531–3537, <https://doi.org/10.3892/or.2017.6050> (2017).
44. Connell, C. M., Colnaghi, R. & Wheatley, S. P. Nuclear survivin has reduced stability and is not cytoprotective. *J. Biol. Chem.* **283**, 3289–3296, <https://doi.org/10.1074/jbc.M704461200> (2008).
45. Chan, K. S., Wong, C. H., Huang, Y. F. & Li, H. Y. Survivin withdrawal by nuclear export failure as a physiological switch to commit cells to apoptosis. *Cell Death Dis.* **1**, e57, <https://doi.org/10.1038/cddis.2010.34> (2010).
46. Aljaberi, A. M., Webster, J. R. & Wheatley, S. P. Mitotic activity of survivin is regulated by acetylation at K129. *Cell Cycle* **14**, 1738–1747, <https://doi.org/10.1080/15384101.2015.1033597> (2015).
47. Fortugno, P. et al. Regulation of survivin function by Hsp90. *Proc. Natl Acad. Sci. USA* **100**, 13791–13796, <https://doi.org/10.1073/pnas.2434345100> (2003).